Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Myriad Genetics has completed a Phase I human clinical trial of MPC-0920, an orally available, direct thrombin inhibitor.
Subscribe to our email newsletter
The trial has studied healthy volunteers in a single, escalating dose format, to determine the safety, dose range and pharmacokinetics of the drug candidate. The results demonstrate significant biological effect on clotting time and a desirable safety profile following oral administration.
MPC-0920 was shown to be absorbed with a very close correlation between the plasma concentration of drug in plasma and an effect on blood clotting as measured by an increase in pro-thrombin time. There were no apparent drug-related adverse events during the study.
The primary objectives of the Phase I trial were to examine the safety and pharmacokinetics of MPC-0920 and a secondary objective was to study the biological activity of MPC-0920. Unlike most Phase I studies, this study showed that a significant biological activity was present and highly correlated to the observed plasma concentration. Myriad intends to aggressively seek a commercial partner for MPC-0920 rather than pursuing further regulatory development independently.